Nick Stone
Senior VP of Investor Relations & Head of Investor Relations – Fresenius Management SE
Hello, everyone. Welcome to the Inaugural Conference Call and Webcast as part of our new Meet the Management series. Today, we’re kicking off with a deep dive into Biopharma. The presentation was e-mailed to our distribution list earlier today and is available on fresenius.com.
On Slide 2 of the presentation, you’ll find the usual safe harbor statement. Unless stated otherwise, we’ll comment using constant exchange rates or CER. In preparation for this call, we asked our investor and analyst research panel about the priority expectations, forgive me.
In short, you told us that you wanted more details on pipeline insights and competitive position, including time lines, scale of pipeline opportunity and differentiation relative to peers. You also asked about the growth drivers and long-term value creation, including greater transparency, revenue and margin impact with a clear growth road map, which we’ve addressed in the presentation and supplementary materials.
Today, I’m delighted to be joined by Michael Sen, Pierluigi, Sang-Jin Pak, and the broader Biopharma team. We will now take you through our ambitions and the agenda on Slide 3 in more detail.
Today’s call will last approximately
